drugset / Trial / NCT00254254

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

NCT00254254

Phase 2 Completed 13 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedCrossoverSingle-blindTreatment

Summary

This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.

Timeline

Start
2006-02
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2.5 ug Subcutaneous
Subject Exenatide Peptide 5 ug Subcutaneous